Immunoepidemiology of Plasmodium vivax MSP-1 and AMA-1 in two previous high malaria endemic districts in Sri Lanka under the prevention of re-establishment phase

Show simple item record

dc.contributor.author Aryachandra, U.
dc.contributor.author Wickremasinghe, R.
dc.contributor.author Fernando, D.
dc.contributor.author Udagama, P.
dc.date.accessioned 2022-02-07T07:59:05Z
dc.date.available 2022-02-07T07:59:05Z
dc.date.issued 2020
dc.identifier.citation Aryachandra U.; Wickremasinghe R.; Fernando D.; Udagama P. (2020), Immunoepidemiology of Plasmodium vivax MSP-1 and AMA-1 in two previous high malaria endemic districts in Sri Lanka under the prevention of re-establishment phase, Proceedings of the Annual Research Symposim, 2020, University of Colombo, 45. en_US
dc.identifier.uri http://archive.cmb.ac.lk:8080/xmlui/handle/70130/6451
dc.description.abstract Sri Lanka was certified malaria free by the WHO in 2016. The presence of the malaria vector in the island, and imported malaria cases pose major risks during the current Prevention of Reestablishment (POR) phase in Sri Lanka. As serological parameters may indicate malaria transmission dynamics, assessment of antimalarial antibody prevalence/titers in populations will be indicative of the status of current infections and hence of malaria transmission. Yet, malaria immunoepidemiology studies in countries successful in eliminating malaria are nonexistent. We aimed to determine the prevalence of antibodies to Plasmodium vivax vaccine candidate antigens, PvMSP1-19 and PvAMA1, in residents of two previous high malaria endemic districts, Hambantota and Kilinochchi; Nuwaraeliya served as the control/malariafree district. Indirect ELISAs assayed antibody responses against two recombinant proteins, PvMSP1-19 and PvAMA1, on serum samples collected with informed consent from study participants. In a total of 3129 individuals (Hambanthota-1231, Kilinochchi-1398, and Nuwaraeliya-500) recruited for the study, Anti-MSP1-19 antibody prevalence was 2.0%, 5.0% and 1.0% while anti-AMA1 antibody prevalence was 5.0%, 14.0% and 2.0% in Hambanthota, Kilinochchi and Nuwaraeliya districts, respectively. Compared to the controls, antibody magnitudes to both PvMSP1-19 and PvAMA1 were significantly higher in Kilinochchi (p<0.005 and p=0.022, respectively) than in Hambantota (p=0.001 and p<0.005). Previous exposure to malaria was significantly associated with antibody responses against both PvMSP1-19 and PvAMA1 among all three districts (p<0.05). In comparison, based on previous records the prevalence of antimalarial antibodies to MSP1-19 and AMA1 in the Hambantota district during 1998–2003 were 59% and 54%, respectively. In conclusion, though significant seroprevalence to P. vivax antigens, MSP1-19 and AMA1, was evident in residents of previous high malaria endemic areas in comparison to a previous malaria non-endemic area under a POR setting, compared to malaria pre-elimination data, these have declined to low levels which may suggest the absence of current malaria transmission. en_US
dc.language.iso en en_US
dc.publisher University of Colombo en_US
dc.subject Immunoepidemiology en_US
dc.subject prevention of re-establishment en_US
dc.subject Plasmodium vivax en_US
dc.subject PvAMA1 en_US
dc.subject PvMSP1-19 en_US
dc.title Immunoepidemiology of Plasmodium vivax MSP-1 and AMA-1 in two previous high malaria endemic districts in Sri Lanka under the prevention of re-establishment phase en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account